Literature DB >> 14999100

A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.

Hal P Bogerd1, Brian P Doehle, Heather L Wiegand, Bryan R Cullen.   

Abstract

The HIV type 1 (HIV-1) virion infectivity factor (Vif) protein blocks the action of the host defense factor APOBEC3G in human cells, thereby allowing release of infectious virions, but fails to inhibit similar APOBEC3G proteins present in some simian cells. Conversely, the Vif protein encoded by the African green monkey (agm) simian immunodeficiency virus (SIV) can block agm APOBEC3G function but fails to inhibit human APOBEC3G. This difference plays a key role in determining the primate species tropism of HIV-1 and SIV agm. Here, we demonstrate that a single APOBEC3G residue, which is an aspartic acid in human APOBEC3G and a lysine in agm APOBEC3G, controls the ability of the HIV-1 Vif protein to bind and inactivate these host defense factors. These data identify a critical charged residue that plays a key role in mediating the formation of the distinct Vif:APOBEC3G complexes formed in human and simian cells. Moreover, these results suggest that the biological barrier preventing the entry of additional SIV into the human population as zoonotic infections is potentially quite fragile.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999100      PMCID: PMC374319          DOI: 10.1073/pnas.0307713101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates.

Authors:  K Tokunaga; M L Greenberg; M A Morse; R I Cumming; H K Lyerly; B R Cullen
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Simian immunodeficiency viruses of diverse origin can use CXCR4 as a coreceptor for entry into human cells.

Authors:  S M Owen; S Masciotra; F Novembre; J Yee; W M Switzer; M Ostyula; R B Lal
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Characterization of a novel simian immunodeficiency virus (SIV) from L'Hoest monkeys (Cercopithecus l'hoesti): implications for the origins of SIVmnd and other primate lentiviruses.

Authors:  V M Hirsch; B J Campbell; E Bailes; R Goeken; C Brown; W R Elkins; M Axthelm; M Murphey-Corb; P M Sharp
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

4.  Functional differences between human and bovine immunodeficiency virus Tat transcription factors.

Authors:  H P Bogerd; H L Wiegand; P D Bieniasz; B R Cullen
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission.

Authors:  J H Simon; D L Miller; R A Fouchier; M A Soares; K W Peden; M H Malim
Journal:  EMBO J       Date:  1998-08-10       Impact factor: 11.598

6.  The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes.

Authors:  J H Simon; M H Malim
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Identification of highly attenuated mutants of simian immunodeficiency virus.

Authors:  R C Desrosiers; J D Lifson; J S Gibbs; S C Czajak; A Y Howe; L O Arthur; R P Johnson
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  Role of Vif in human immunodeficiency virus type 1 reverse transcription.

Authors:  J Goncalves; Y Korin; J Zack; D Gabuzda
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

9.  Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.

Authors:  U von Schwedler; J Song; C Aiken; D Trono
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Subcellular localization of the Vif protein of human immunodeficiency virus type 1.

Authors:  J Goncalves; P Jallepalli; D H Gabuzda
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

View more
  174 in total

1.  Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo.

Authors:  Rodolphe Suspène; Marie-Ming Aynaud; Stefanie Koch; David Pasdeloup; Marc Labetoulle; Barbara Gaertner; Jean-Pierre Vartanian; Andreas Meyerhans; Simon Wain-Hobson
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

3.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

4.  A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif.

Authors:  John S Albin; Rebecca S LaRue; Jessalyn A Weaver; William L Brown; Keisuke Shindo; Elena Harjes; Hiroshi Matsuo; Reuben S Harris
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

5.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

6.  Controlling lentiviruses: single amino acid changes can determine specificity.

Authors:  Shari M Kaiser; Michael Emerman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

7.  Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Authors:  Erez Pery; Ann Sheehy; N Miranda Nebane; Andrew Jay Brazier; Vikas Misra; Kottampatty S Rajendran; Sara J Buhrlage; Marie K Mankowski; Lynn Rasmussen; E Lucile White; Roger G Ptak; Dana Gabuzda
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

8.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

9.  Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages.

Authors:  Zhujun Ao; Xiaoxia Wang; Alexander Bello; Kallesh Danappa Jayappa; Zhe Yu; Keith Fowke; Xinying He; Xi Chen; Junhua Li; Gary Kobinger; Xiaojian Yao
Journal:  Hum Gene Ther       Date:  2011-03-18       Impact factor: 5.695

10.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.